Epilepsy and Parkinson's Disease: Drugs
The question
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure consistency of the supply of medication for (a) epilepsy and b) Parkinson's disease patients.
Answered by Karin Smyth
The Department is working hard with industry to help resolve intermittent supply issues with some epilepsy medications. As a result of ongoing activity and intensive work, including directing suppliers to expedite deliveries, some issues, including with some carbamazepine and oxcarbazepine presentations, have been resolved.
There was a supply issue with all strengths of lamotrigine tablets, used to manage epilepsy, due to manufacturing issues. The supply issue has recently resolved, and supply is expected to return to normal levels through early December 2024.
We are aware of an ongoing supply issue with all strengths of topiramate tablets, with the resupply date to be confirmed. Other manufacturers of topiramate tablets can meet the increased demand during this time.
The Department is aware of supply constraints with one supplier of amantadine 100 milligram capsules, used in the management of Parkinson’s disease, however stocks remain available from alternative suppliers to cover this demand.
The Department continues to work closely with industry, the National Health Service, and others to help ensure patients continue to have access to an alternative treatment until their usual product is back in stock.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →